A Study to Evaluate the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain

Overview

Información sobre este estudio

The purpose of this study is to assess the safety of the Angel® Concentrated Platelet Rich Plasma System and Angel® CPRP Processing Set to process Platelet Rich Plasma for intra-articular injection into four lumbar facet joints (2 levels) causing chronic low back pain.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Clinical and radiographic (MRI, CT or lumbar x-ray) evidence of symptomatic facet
arthropathy involving the bilateral bottom two facets (e.g., L4-5 or L5-6 and L5-S1 or
L6-S1).

- Positive response, defined according to current clinical standards for the diagnosis
of facet-mediated low back pain as greater than or equal to 75% pain improvement (as
reported by patient) to diagnostic medial branch nerve blocks, one block with
lidocaine and the other with bupivacaine.

- Low back pain VAS score of greater than or equal to 5 at the clinical visit just prior
to the first medial branch nerve block.

Exclusion Criteria:

- Prior facet related procedure (intraarticular corticosteroid injection, radiofrequency
ablation (RFA)) in last 6 months or prior fusion in the bottom two facets.

- Current opioid use of greater than 50mg oral morphine milligram equivalents per day.

- No advanced imaging (MRI, CT or lumbar x-ray) of the lumbar spine within the last 6
months.

- BMI > 34.99 (WHO class I obesity).

- Active systemic or local infection as evidenced by fever >100.4 degrees Fahrenheit, or
any other clinical signs or symptoms of infection within 24 hours of the procedure.

- On anticoagulation drug and has been on hold for less than 7 days prior to the
investigational procedure.

- Imaging evidence of high likelihood of failure for intra-articular injection in the
opinion of the PI or delegate review of MRI, CT or lumbar x-ray imaging.

- History of chronic thrombocytopenia (or pre-operative platelet count less than 195,000
per ?l).

- Undergoing chemotherapy at time of injection.

- Pregnant or breastfeeding.

- Use of illicit drugs within 30 days prior to study entry.

- NSAID use during the pre-procedural period (one week before Treatment Day 0).

- Preoperative hematocrit less than 36%.

- History of hemodynamic instability or inability to maintain stable oncotic pressure.

- History of prolonged clotting times.

- Prior history of lumbar procedure.

- Redness, swelling, rash or other concerning lesions at the injection site just prior
to the procedure.

- Prior history of allergy to lidocaine or other local anesthetic agent.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 2/21/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Matthew Pingree, M.D.

Cerrado para la inscripción

Contact information:

Matthew Pingree M.D.

(507) 266-9240

Pingree.Matthew@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20516956

Mayo Clinic Footer